Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
Pulmonary fungal infection in the immunocompromised patient
Essential points for quick revision.
2 min synopsisUK scopeSources checked 27 Aug 2026Clinical review pending
!
Escalate
A severely immunocompromised patient with new hypoxaemia, haemoptysis, pleuritic pain or compatible CT change needs urgent specialist assessment, sampling that does not delay care and prompt empiric antifungal treatment when invasive disease is strongly suspected.
Synopsis
Recognise invasive pulmonary fungal disease as a time-critical syndrome, combine host risk, CT, biomarkers and respiratory sampling, and start species-directed antifungal treatment with expert support without waiting for perfect proof. Treatment must be individualised with haematology, transplant, HIV, respiratory, microbiology and pharmacy input.
Prolonged neutropenia, allogeneic stem-cell transplantation, solid-organ transplantation, high-dose or prolonged corticosteroids and major T-cell suppression create different fungal risks.
Persistent or recurrent fever despite broad antibacterial therapy may be the only early sign; cough, pleuritic pain or haemoptysis can appear late.
Urgent thin-section CT is more sensitive than a chest radiograph: nodules, halo sign, wedge-shaped infarcts, cavitation or reversed halo should accelerate specialist review.
Key red flags
High-risk febrile host
Persistent or recrudescent fever during prolonged neutropenia, after allogeneic transplantation or under intensive corticosteroid or T-cell suppressive therapy should trigger urgent fungal-risk review even with a normal chest radiograph.
Investigation priorities
01
Urgent thin-section CT chestFirst step
Detect early nodules, halo or reversed-halo patterns, infarcts, cavitation, airway lesions and a target for BAL or biopsy.
Management branches
EscalateProbable invasive fungal pneumonia
A high-risk host has persistent fever or respiratory deterioration with compatible CT findings.
Stabilise oxygenation and sepsis physiology, obtain blood cultures and urgent CT, and involve haematology or transplant, infection or microbiology, respiratory medicine and antifungal pharmacy.
Send serum biomarkers and pursue BAL or tissue only if the expected diagnostic benefit justifies procedural risk; capture details of prophylaxis and prior antifungal exposure.
Key medicines
VoriconazoleFor serious invasive aspergillosis, the SmPC describes loading followed by maintenance, commonly intravenous 6 mg/kg every 12 hours for 24 hours then 4 mg/kg every 12 hours, with an oral adult maintenance option; specialists must adjust using exposure, weight, liver function and interactions.
Liposomal amphotericin BIntravenous weight-based specialist regimen; 3 mg/kg daily is used for many systemic fungal infections, while suspected mucormycosis may require a different higher specialist dose. Confirm current SmPC and local mycology advice.
National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.